Irina I. Kaptsan

Irina I. Kaptsan

Auto-generated profile, based on publicly available information

Irina I. Kaptsan

Department of Plastic and Reconstructive Surgery, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2025 in JPRAS Open
Verified
Journal Article
Open access
PKPatrick J. Kennedy
Patrick J. Kennedy
MOMolly A. Olson
Molly A. Olson
IKIrina I. Kaptsan
Irina I. Kaptsan
JBJonathan Bernard
Jonathan Bernard
BOBen Ormseth
Ben Ormseth
JJJeffrey Janis
Jeffrey Janis
Obesity is a risk factor for diabetes mellitus (DM), which is associated with impaired wound healing and increased surgical site infections (SSI) due to poor vascularity. Patients who undergo abdominoplasties or panniculectomies often have multiple comorbidities, including DM and obesity. Previous research has demonstrated that adequate perioperative glycemic control is crucial to decreasing the risk of postoperative wound complications; however, the impact of diabetic pharmacology and HbA1c levels on postoperative outcomes in patients who undergo abdominoplasties or panniculectomies has not been studied. We conducted a retrospective cohort study on patients aged 18–85 who underwent abdominoplasty or panniculectomy at our institution from July 2014 to April 2023. Patients were stratified by HbA1c levels into four categories: Normal (<5.7), Prediabetic (5.7–6.4), Diabetic (6.5–6.9), and Diabetic with uncontrolled hyperglycemia (7.0–8.9). Diabetic patients were also categorized based on their diabetic medication use. Postoperative outcomes, including SSI, seroma, hematoma, readmission, and reoperation, were analyzed. Among the 594 patients, 16.3 % had DM, and 6.6 % were on anti-diabetic medications. SSIs occurred in 24.2 % of patients, with no significant differences between groups (p = 0.28). This study did not establish a clear relationship between diabetes medication regimens and poor postoperative outcomes; however, it highlights the medical complexity of patients who undergo abdominoplasty or panniculectomy and the perioperative glycemic management. Further research is needed to investigate how to better optimize diabetes management for improved surgical outcomes.

18 October 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
RDRavi Dhital
Ravi Dhital
KFKaitlyn Flint
Kaitlyn Flint
IKIrina Kaptsan
Irina Kaptsan
SHShweta Hegde
Shweta Hegde
RDReem Daloul
Reem Daloul
MSMasako Shimamura
Masako Shimamura
CMV infection and Th17 cells are independently associated with increased risk for late allograft loss after renal transplantation. Although CMV-specific Th17 cells are detectable in animal models and nontransplant clinical populations, evidence linking CMV and Th17 cells after renal transplantation remains unclear. This prospective observational study evaluated a cohort of renal transplant recipients during 12 mo posttransplant to assess the presence of CMV-specific Th17 cells in peripheral blood and their relationship to pretransplant CMV serostatus and CMV DNAemia. CMV-specific Th17 cells were identified among CMV serostatus donor (D)+ and/or recipient (R)+ recipients and expanded during both primary (D+/R−) and reactivated (D+/R+, D−/R+) CMV DNAemia. A subset of CMV-specific Th17 cells coexpressed IFN-γ, indicating a Th1/17 phenotype. These Th17 and Th1/17 cells expressed CCR6, CCR5, activation and terminal differentiation markers (CD95, OX40, HLA-DR, CD57), and a central/effector memory phenotype. CMV-specific Th1/17 cells expressed activating/inhibitory receptors (CD57, 4-1BB, CD160, CTLA-4, PD-1) at higher frequencies than Th17 cells. In contrast, staphylococcal enterotoxin B–induced Th17 cells did not expand during CMV DNAemia, did not differ between CMV serostatus groups over time, expressed CCR6, predominantly coexpressed TNF-α, and had lower expression of activating and inhibitory receptors than pp65-specific Th17 and Th1/17 cells. These data show that CMV-specific Th17 cells expand during episodes of CMV DNAemia among renal transplant recipients, and that these virus-specific Th17 and Th1/17 cells have distinct phenotypes from global circulating Th(1)/17 cells. These results suggest a potential proinflammatory pathway by which CMV-induced Th17 cells may contribute to allograft injury, increasing risk for late allograft loss.